A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking
The aim of this study was to investigate the possible reduced risk of Parkinson Disease (PD) due to coffee, alcohol, and/or cigarette consumption. In addition, we explored the potential effect modification by intensity, duration and time-since-cessation of smoking on the association between cumulative pack-years of cigarette smoking (total smoking) and PD risk. Data of a hospital based case-control study was used including 444 PD patients, diagnosed between 2006 and 2011, and 876 matched controls from 5 hospitals in the Netherlands. A novel modeling method was applied to derive unbiased estimates of the potential modifying effects of smoking intensity, duration, and time-since-cessation by conditioning on total exposure. We observed no reduced risk of PD by alcohol consumption and only a weak inverse association between coffee consumption and PD risk. However, a strong inverse association of total smoking with PD risk was observed (OR = 0.27 (95%CI: 0.18–0.42) for never smokers versus highest quartile of tobacco use). The observed protective effect of total smoking was significantly modified by time-since-cessation with a diminishing protective effect after cessation of smoking. No effect modification by intensity or duration of smoking was observed indicating that both intensity and duration have an equal contribution to the reduced PD risk. Understanding the dynamics of the protective effect of smoking on PD risk aids in understanding PD etiology and may contribute to strategies for prevention and treatment.
References
[1]
Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of parkinson's disease: A review of the evidence. Eur J Epidemiol 26 Suppl 1S1–58.
[2]
Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of parkinson's disease. Ann Neurol 52: 276–284.
[3]
Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, et al. (2007) Pooled analysis of tobacco use and risk of parkinson disease. Arch Neurol 64: 990–997.
[4]
Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R (2004) Smoking and parkinson's disease: Systematic review of prospective studies. Mov Disord 19: 614–621.
[5]
Chen H, Huang X, Guo X, Mailman RB, Park Y, et al. (2010) Smoking duration, intensity, and risk of parkinson disease. Neurology 74: 878–884.
[6]
Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, et al. (2007) Temporal relationship between cigarette smoking and risk of parkinson disease. Neurology 68: 764–768.
[7]
Lubin JH, Caporaso NE (2006) Cigarette smoking and lung cancer: Modeling total exposure and intensity. Cancer Epidemiol Biomarkers Prev 15: 517–523.
[8]
Vlaanderen J, Portengen L, Schuz J, Olsson A, Pesch B, et al. (2014) Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: A flexible method applied to cigarette smoking and lung cancer in the SYNERGY study. Am J Epidemiol 179: 290–298.
[9]
Oostenbrink JB, Rutten FF (2006) Cost assessment and price setting of inpatient care in the netherlands. the DBC case-mix system. Health Care Manag Sci 9: 287–294.
[10]
Rothman KJ, Greenland S, Lash TL (2008) Case-Control Studies. In: Modern Epidemiology: Lippincott Williams & Wilkins. pp. 111–127.
[11]
Quik M, O'Leary K, Tanner CM (2008) Nicotine and parkinson's disease: Implications for therapy. Mov Disord 23: 1641–1652.
[12]
Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for parkinson's disease. Mov Disord 27: 947–957.
[13]
Dagher A, Robbins TW (2009) Personality, addiction, dopamine: Insights from parkinson's disease. Neuron 61: 502–510.
[14]
Menza M (2000) The personality associated with parkinson's disease. Curr Psychiatry Rep 2: 421–426.
[15]
Ishihara L, Brayne C (2006) What is the evidence for a premorbid parkinsonian personality: A systematic review. Mov Disord 21: 1066–1072.
[16]
Savica R, Rocca WA, Ahlskog JE (2010) When does parkinson disease start? Arch Neurol 67: 798–801.
[17]
Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, et al. (2002) Smoking and parkinson's disease in twins. Neurology 58: 581–588.
[18]
Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL (2005) Risk and protective factors for parkinson's disease: A study in swedish twins. Ann Neurol 57: 27–33.
[19]
Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010) Caffeine exposure and the risk of parkinson's disease: A systematic review and meta-analysis of observational studies. J Alzheimers Dis 20 Suppl 1S221–38.
[20]
Liu R, Guo X, Park Y, Huang X, Sinha R, et al. (2012) Caffeine intake, smoking, and risk of parkinson disease in men and women. Am J Epidemiol 175: 1200–1207.
[21]
Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, et al. (2009) Adenosine, adenosine A 2A antagonists, and parkinson's disease. Parkinsonism Relat Disord 15: 406–413.
[22]
Ishihara L, Brayne C (2005) A systematic review of nutritional risk factors of parkinson's disease. Nutr Res Rev 18: 259–282.